Please use this identifier to cite or link to this item:
Title: Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study
Authors: Carabante-Ocón, F
Saez-Lara, E
Burgos-Garcia, L
Villar-Chamorro, E
Casaus-Hazañas, A
Luna, S
Martínez, C
metadata.dc.contributor.authoraffiliation: [Carabante-Ocón,F; Saez-Lara, E; Burgos-Garcia, L; Villar-Chamorro, E; Casaus-Hazañas, A; Luna, S; Martínez, C] Unidad de Mama, Hospital Carlos Haya, Málaga, Spain.
Keywords: trastuzumab;her2-positive;chemotherapies;MBC;neoplasias de la mama;Retratamiento
metadata.dc.subject.mesh: Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Retreatment
Issue Date: 19-Jun-2007
Publisher: BioMed Central
Citation: Carabante-Ocón F, Saez-Lara E, Burgos-Garcia L, Villar-Chamorro E, Casaus-Hazañas A. Luna S, et al. Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study. Breast Cancer Research. 2007 Jun;9 Supplement 1:s17-8
Abstract: Objective: To study the benefit of trastuzumab in monotherapy or combined with different chemotherapeutic agents in the treatment for Her2+ metastatic breast cancer (MBC) patients after progression on prior trastuzumab therapy.
metadata.dc.identifier.doi: 10.1186/bcr1708
ISSN: 1465-5411 (Print)
1465-542X (Online)
Appears in Collections:01- Artículos - Hospital Regional de Málaga

Files in This Item:
File Description SizeFormat 
CarabantesOcon_RetreatmentWithTrastuzumab.pdfPoster52,4 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons